Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Driver Mutation Positive Non-small Cell Lung Cancer”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Not applicableStudy completedNCT04552613
What this trial is testing

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

Who this might be right for
Non-small-lung-cell CancerNSCLCEGFR Gene Mutation
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 114
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07314216
What this trial is testing

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

Who this might be right for
NSCLC (Non-small Cell Lung Carcinoma)Stage IIIEGFR Uncommon Mutations
Hunan Cancer Hospital 15
Large-scale testing (Phase 3)Looking for participantsNCT05236946
What this trial is testing

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Who this might be right for
Asymptomatic Brain MetastasesDriver Mutation Positive Non-small Cell Lung Cancer
Tata Memorial Hospital 190
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166